ESPE Abstracts

Abstract unavailable....

Background: SWEET (www.sweet-project.eu) is a non-profit entity endorsed by ISPAD aiming to create an extensive network of certified CoRs for childhood diabetes in order to ensure high quality care.Objective and hypotheses: SWEET aims at an improved and more uniform care for people with diabetes through comparing processes and outcomes among participating members. The results of data analysis are conveyed to memb...

Background: A large percentage of pediatric patients with type 1 diabetes (T1D) do not achieve their glycaemic targets. The most impactful benefit can be achieved by improving the implementation of novel technologies developed to manage diabetes.Objective and hypotheses: Two novel technologies were introduced to help patients with T1D achieve glycaemic control: continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM). They ...

Background: Blood glucose levels are physiologically controlled by insulin and counter-regulatory hormones, mainly glucagon. Type 1 diabetes patients are deficient in insulin and some level also glucagon. Therefore, bi-hormonal closed-loop system seems to be the best way to control glycemia.Objective and hypotheses: There are two main approaches to add glucagon: (a) as safety measures for rescue in case of hypoglycemia (2) as a mean to optimize metabolic...

Dual hormone closed-loop insulin/glucagon delivery has been successfully used in in- and out-patient clinical setting with a reduction in hypoglycemia and improvement in time in range of glucose concentration. However, the main goal of the dual hormone closed-loop systems – complete prevention of hypoglycemia – has not been achieved. In the latest published studies with dual hormone closed-loop systems the amount of intervention with oral carbohydrates is still almos...

Management of Type1 diabetes is a challenge for both patients and health-care providers. The majority of patients worldwide are not reaching the desired glycemic control. Barriers to good control include risk of hypoglycemia, glucose monitoring limitations, technologies of insulin administration, scarceness of diabetes experts their limited time required in order to give the appropriate level of personalized treatment and supervision during patients’ visits. Other reasons...

Background: Research has demonstrated that technologies to support diabetes self-management for people living with diabetes can have positive effects on medical and quality of life outcomes. It also shows that there may be an additional burden of wearing and using these technologies. Both diabetes and its treatment can have significant deleterious effect on quality of life, thus it is crucial that the interaction between the technology and the user offers maximum benefit with ...